

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>17</b>
<b>1. Introduction to cancer therapy .....</b>	<b>19</b>
<b>Molecular biology of cancer .....</b>	<b>19</b>
The genesis of cancer .....	19
<i>Normal cell cycle and growth .....</i>	<i>19</i>
<i>Oncogenes .....</i>	<i>20</i>
<i>Tumor Suppressor Genes .....</i>	<i>20</i>
<i>Role of microRNAs in cancer .....</i>	<i>22</i>
<i>Role of Bub 1 gene in cell division .....</i>	<i>22</i>
<i>Mechanism of DNA damage in Fanconi anemia leading to leukemia .....</i>	<i>23</i>
<i>Accumulation of random mutations .....</i>	<i>23</i>
<i>Chromosomal instability .....</i>	<i>23</i>
<i>Aneuploidy .....</i>	<i>24</i>
<i>Telomeres and cancer .....</i>	<i>24</i>
<i>DNA methylation and cancer .....</i>	<i>25</i>
<i>Anticancer treatments based on RNA regulation of genes .....</i>	<i>25</i>
Hallmarks of cancer .....	26
Self-sufficiency of tumor proliferation .....	26
Apoptosis .....	27
<i>Therapeutic implications of apoptosis in cancer .....</i>	<i>27</i>
<i>Autophagy .....</i>	<i>29</i>
Tumor angiogenesis .....	29
Acquisition of a potential for unlimited replication .....	31
Invasion and metastases .....	31
<i>Tumor suppressor genes and metastases .....</i>	<i>32</i>
<b>Cancer biomarkers .....</b>	<b>32</b>
Molecular imaging of cancer .....	32
<b>Cancer genomics .....</b>	<b>33</b>
Gene expression profiling in cancer .....	33
<b>Cancer proteomics .....</b>	<b>33</b>
<b>Limitations of genomics and proteomics for understanding cancer .....</b>	<b>34</b>
<b>Cancer microenvironment .....</b>	<b>34</b>
<b>Epidemiology of cancer .....</b>	<b>35</b>
<b>Current management of cancer .....</b>	<b>35</b>
Chemotherapy .....	36
<i>Limitations of cancer chemotherapy .....</i>	<i>36</i>
Radiotherapy .....	36
<i>Brachytherapy .....</i>	<i>37</i>
Surgery .....	37
<b>Basics of drug delivery in cancer .....</b>	<b>37</b>
<b>Historical landmarks in cancer drug delivery .....</b>	<b>37</b>
<b>2. Innovative treatments for cancer .....</b>	<b>39</b>
<b>Introduction .....</b>	<b>39</b>
<b>Selective estrogen receptor modulators .....</b>	<b>40</b>
<b>Antiangiogenic strategies for cancer .....</b>	<b>41</b>
Development of antiangiogenic therapies .....	41
Classification of antiangiogenic agents .....	41
Examples of antiangiogenic agents .....	43
<i>Chemotherapy at lower than maximum tolerated dose .....</i>	<i>43</i>
<i>Galectin-3 as a target for inhibiting angiogenesis .....</i>	<i>43</i>
<i>Inhibitors of endothelial proliferation .....</i>	<i>43</i>
<i>Inducers of apoptosis of endothelial cells of tumor vessels .....</i>	<i>44</i>
<i>Lodamin .....</i>	<i>44</i>
<i>Matrix metalloproteinase inhibitors .....</i>	<i>44</i>
<i>Monoclonal antibodies with vasculostatic properties .....</i>	<i>45</i>
<i>PPAR<math>\alpha</math> agonists .....</i>	<i>46</i>
<i>Rapalogues as antiangiogenic agents .....</i>	<i>47</i>
<i>VEGF Trap .....</i>	<i>47</i>
Agents that decrease the permeability of tumor blood vessels .....	47
Antiangiogenic agents in clinical trials .....	48
Combination of antiangiogenic with cytotoxic therapy .....	48
<b>Bacterial anticancer agents .....</b>	<b>48</b>
Tumor-targeted bacteria .....	49
<i>Genetically modified Salmonella typhimurium as anticancer agent .....</i>	<i>50</i>
<i>TAPET (Tumor Amplified Protein Expression Therapy) .....</i>	<i>50</i>

<i>Bacterial protein for targeted delivery of liposomal cancer drugs</i> .....	50
Killed but metabolically active (KBMA) bacteria .....	51
Bacterial toxins targeted to tumors .....	51
<i>Immunotoxins</i> .....	51
<i>Escherichia Coli toxins</i> .....	51
<i>Engineered anthrax toxin</i> .....	52
<i>Recombinant fusion toxins</i> .....	52
Type III secretion systems .....	54
Induction of apoptosis in cancer by bacterial proteins .....	54
Induction of immune response by bacteriolytic therapy .....	54
<b>Innovations in cell therapy for cancer</b> .....	<b>55</b>
Stem cell transplantation for cancer .....	56
Cancer drug/gene delivery by mesenchymal stem cells.....	56
<b>Cancer immunotherapy</b> .....	<b>56</b>
Cytokines.....	57
Cancer vaccines .....	57
<i>5T4 as a target for cancer immunotherapy</i> .....	58
<i>Anti-telomerase vaccine</i> .....	59
<i>Antigen-specific cancer vaccines</i> .....	59
<i>Carcinoembryonic antigen-based vaccines</i> .....	60
<i>Dendritic cells for cancer vaccination</i> .....	60
<i>Hybrid cell vaccination</i> .....	62
<i>Adoptive cell therapy</i> .....	63
<i>Tumor cell vaccines</i> .....	64
<i>Vaccines that simultaneously target different cancer antigens</i> .....	65
Concluding remarks about cancer vaccines.....	66
Chemoimmunotherapy .....	66
Cancer Vaccine Consortium .....	66
<b>Innovative methods of radiation delivery</b> .....	<b>66</b>
Image-guided ultrasound technology for delivery of radiation .....	67
Respiratory gating technology for radiation therapy.....	67
Positron therapy .....	67
Boron neutron capture therapy .....	68
<i>Application of drug delivery systems to BNCP</i> .....	68
<i>Use of nanotechnology to enhance BNCT</i> .....	68
Skeletal Targeted Radiotherapy .....	69
<b>Irreversible electroporation</b> .....	<b>69</b>
<b>Methods to overcome multidrug resistance (MDR)</b> .....	<b>70</b>
P-glycoprotein-mediated MDR.....	70
MDR-associated protein gene .....	70
Strategies for overcoming MDR.....	71
<i>Blocking the action of P-glycoprotein</i> .....	71
<i>Combination of targeted drugs with different specificities</i> .....	71
<i>Enzyme Catalyzed Therapeutic Activation</i> .....	72
<i>Inhibition of DNA repair</i> .....	72
<i>Iron chelators that overcomes resistance to chemotherapeutics</i> .....	72
<i>Liposome formulation of drugs</i> .....	73
<i>Modification of the chemical structure of the anticancer drug</i> .....	73
<i>Managing resistance to antiapoptotic action of anticancer agents</i> .....	73
<i>Modulation of SPARC expression</i> .....	74
<i>Nitric oxide inducers</i> .....	74
<i>Proton pump inhibitors</i> .....	74
<i>Repression of Prohibitin1 in drug-resistant cancer cells</i> .....	74
<b>Targeted cancer therapies</b> .....	<b>75</b>
Targeting cellular pathways.....	75
Targeting antigens in virus-associated cancer .....	75
Targeting HAAH for cancer therapy .....	76
Targeting the IGF-I receptor.....	76
Targeting Mcl-1 protein.....	76
Targeting mitochondrial membranes.....	76
Targeting tumor lymphatics.....	78
Targeting tyrosine kinase receptors.....	78
<i>Inhibitors of bcr-abl tyrosine kinase</i> .....	79
<i>Inhibition of multiple tyrosine kinases</i> .....	79
<i>Inhibitors of ErbB tyrosine kinase</i> .....	79
Targeting the Hedgehog signaling pathway .....	80
Targeting caspase-8 .....	80
Targeting oncogenes .....	81
Targeting miRNA for cancer therapeutics .....	82
Targeting the transferrin receptor-mediated endocytosis pathway .....	82
Targeted anticancer therapies based on the Rad51 promoter.....	82

Targeting cancer stem cells .....	82
Targeting glycolytic pathway in cancer .....	83
Targeting glycoproteins .....	84
<i>Tagging cancer with modified sugars</i> .....	84
<i>Anticancer agents based on glycobiology</i> .....	84
<i>Targeting cell surface glycoproteins</i> .....	84
<i>Biofusion for targeted cancer therapy</i> .....	85
<b>Enhancing the effects of radiation and chemotherapy .....</b>	<b>85</b>
Sensitizing agents for chemotherapy .....	86
<i>Tesmilifene for chemosensitization</i> .....	86
<i>CoFactor to enhance the efficacy of chemotherapy</i> .....	86
<i>Enzyme-enhanced chemotherapy</i> .....	86
Sensitizing agents for radiotherapy .....	87
<i>IPdR</i> .....	87
Manipulation of tumor oxygenation .....	87
<i>Hypoxia-based methods to enhance chemotherapy and radiotherapy</i> .....	88
<i>Hyperbaric oxygen and radiation</i> .....	88
<i>HIF-1 antagonists to enhance radiotherapy</i> .....	89
<i>Nonsteroidal antiinflammatory drugs enhance tumor radiosensitivity</i> .....	89
<i>ONCONASE as radiosensitivity enhancer</i> .....	89
Hyperthermia and chemotherapy/radiation therapy .....	89
<i>Techniques for hyperthermia</i> .....	90
<i>Trimodality therapy: radiation, chemotherapy, and hyperthermia</i> .....	90
Photodynamic therapy .....	91
<b>Novel anticancer agents .....</b>	<b>93</b>
Anti-EphA2 antibodies .....	93
Antioxidants .....	93
Brostallicin .....	94
Agents disrupting folate metabolism .....	94
<i>Pemetrexed</i> .....	94
Cell cycle inhibitors .....	94
Cytotoxic ribonucleases .....	95
DNA hypomethylating agents .....	95
Histone-based cancer therapy .....	95
<i>Histone deacetylase inhibitors</i> .....	96
<i>Modulation of p300/CBP histone acetyltransferase activity</i> .....	96
<i>Simulation of endogenous histone for anticancer therapy</i> .....	97
HSP90 inhibitors .....	97
Ion channel blockers .....	98
<i>IOT-101</i> .....	98
<i>Endovion</i> .....	98
LPAAT-beta inhibitors .....	98
Modulation of pyruvate kinase M2 .....	99
P13-kinase inhibitors .....	99
PARP inhibitors .....	99
<i>Targeted destruction of BRCA2 deficient tumors by PARP inhibitors</i> .....	100
Prodrugs .....	100
<i>Enzyme-activated prodrugs</i> .....	100
<i>Ascorbic acid as a prodrug for cancer</i> .....	101
<i>Prolarix</i> .....	101
Protein kinase G activation .....	101
Proteasome inhibitors .....	102
Recombinant human insulin-like growth factor binding protein-3 .....	102
Second generation nucleosides .....	103
Targeting topoisomerase IB .....	103
Telomerase inhibitors .....	104
Therapeutic strategies based on the P53 pathway .....	104
Therapeutic strategies based on molecular mechanisms .....	105
<i>Checkpoint activation as a strategy against cancer</i> .....	105
<i>Deletion-specific targeting for cancer therapy</i> .....	105
<i>In vivo models for molecularly anticancer drugs</i> .....	106
<i>Repair-blocking drugs for enhancing effect of chemotherapy</i> .....	106
<i>Targeting mTOR signaling defects</i> .....	106
Combining novel anticancer approaches .....	107
<b>Personalized therapy of cancer .....</b>	<b>108</b>
Challenges of cancer classification .....	110
Design of future cancer therapies .....	110
Personalized drug development in oncology .....	111
<i>Role of molecular imaging</i> .....	111
<i>Role of molecular imaging in targeted cancer therapy</i> .....	112
<i>Screening for personalized anticancer drugs</i> .....	112

<b>3. Drug delivery systems for cancer.....</b>	<b>115</b>
<b>Introduction.....</b>	<b>115</b>
<b>Routes of drug delivery in cancer.....</b>	<b>115</b>
Intravenous delivery systems for cancer therapy .....	116
<i>Intravenous versus oral ascorbate for treatment of cancer</i> .....	117
Subcutaneous injection of anticancer agents .....	117
Oral delivery of anticancer agents .....	117
Oral UFT .....	118
5-FU combined with eniluracil .....	118
Oral paclitaxel .....	119
Oral fluoropyrimidines .....	119
Oral satraplatin .....	120
Oral PXD101 .....	120
ARRY-142886 .....	121
High dose pulse administration of calcitrol .....	121
Oral gefitinib vs intravenous docetaxel.....	121
Transdermal drug delivery .....	121
Delivery of the photosensitizer drug $\delta$ -amino levulinic acid .....	122
Transdermal delivery of the methotrexate .....	122
Transdermal nitroglycerine for prostate cancer .....	122
Transdermal delivery of peptide cancer vaccines .....	123
Intradermal delivery of cancer vaccines by adenoviral vectors .....	123
Pulmonary delivery of anticancer agents .....	123
Regional intra-arterial delivery of chemotherapy .....	124
Gas embolotherapy of tumors.....	124
Drug delivery to lymph nodes.....	125
Intraperitoneal macrophages as drug delivery vehicle.....	125
Challenges of cancer drug delivery .....	125
Tumor blood vessel pore barrier to drug delivery .....	125
Improvement of drug transport in tumors .....	126
Delivery of anticancer drugs to nuclear targets .....	126
<b>Innovative formulations for drug delivery in cancer .....</b>	<b>127</b>
Cancer targeting with polymeric drugs.....	127
Linking anticancer drugs to polyglutamate.....	128
Improving delivery of protein-polymer anticancer drugs.....	128
Macromolecules as delivery systems for taxanes .....	129
Polyamine conjugates as anticancer agents .....	129
Bacterial ghosts as drug delivery systems for anticancer drugs .....	129
Microparticles as therapeutic delivery systems in cancer .....	130
Subcutaneous injection of microspheres carrying anticancer drugs .....	130
Intravascular delivery systems using microparticles.....	131
Tumor embolization with drug-eluting beads .....	131
Tumor embolization with radioactive microparticles .....	131
Microparticles heated by magnetic field.....	132
Magnetic targeted microparticle technology .....	132
Release of drugs from micelles by ultrasound .....	132
Release of drugs from biSphere by ultrasound .....	133
Release of drugs from microcapsules by laser .....	133
Chemoembolization .....	133
Anticancer drugs bound to carbon particles .....	134
Anticancer drugs bound to protein microspheres .....	134
Nanoerythroosomes .....	134
Micronized droplets of olive oil .....	134
<b>Nanobiotechnology-based drug delivery for cancer .....</b>	<b>135</b>
Nanoparticle formulations for drug delivery in cancer .....	136
Anticancer drug particles incorporated in liposomes.....	136
Encapsulating drugs in hydrogel nanoparticles .....	138
Exosomes .....	138
Folate-linked nanoparticles.....	139
Lipid based nanocarriers .....	139
Micelles for drug delivery in cancer.....	139
Minicells for targeted delivery of nanoscale anticancer therapeutics .....	141
Nanobombs for cancer .....	141
Nanodiamonds for local delivery of chemotherapy at site of cancer .....	142
Nanoparticle formulation for enhancing anticancer efficacy of cisplatin .....	142
Nanoparticle formulations of paclitaxel.....	142
Nanoparticles containing albumin and antisense oligonucleotides .....	143
Non-aggregating nanoparticles .....	143
Pegylated nanoliposomal formulation .....	143

<i>Perfluorocarbon nanoparticles</i> .....	144
<i>Polypeptide-doxorubicin conjugated nanoparticles</i> .....	144
<i>Protosphere nanoparticle technology</i> .....	144
Nanoparticles for targeted delivery of drugs into the cancer cells .....	145
<i>Antiangiogenic therapy using nanoparticles</i> .....	146
<i>Carbon magnetic nanoparticles for targeted drug delivery in cancer</i> .....	146
<i>Carbon nanotubes for targeted drug delivery to cancer cells</i> .....	147
<i>DNA aptamer-micelle for targeted drug delivery in cancer</i> .....	147
<i>Fullerenes for enhancing tumor targeting by antibodies</i> .....	147
<i>Gold nanoparticles for targeted drug delivery in cancer</i> .....	148
<i>Iron oxide magnetic nanoparticle formulation for drug delivery</i> .....	149
<i>Lipoprotein nanoparticles targeted to cancer-associated receptors</i> .....	149
<i>Magnetic nanoparticles for remote-controlled drug delivery to tumors</i> .....	150
<i>Nanobees for targeted delivery of cytolytic peptide melittin</i> .....	150
<i>Nanocell for targeted drug delivery to tumor</i> .....	151
<i>Nanodroplets for site-specific cancer treatment</i> .....	151
<i>Nanoparticle-mediated targeted delivery of peptides into tumors</i> .....	152
<i>Nanoparticle-mediated targeting of MAPK signaling pathway</i> .....	152
<i>Nanoparticles for targeted delivery of concurrent chemoradiation</i> .....	152
<i>Nanostructured hyaluronic acid for targeted drug delivery in cancer</i> .....	153
<i>Nanoparticles as antibody-drug conjugates</i> .....	153
<i>Nanoparticle-coated peptides for tumor targeting</i> .....	153
<i>Polymer nanoparticles for targeted drug delivery in cancer</i> .....	153
<i>Polymerosomes for targeted cancer drug delivery</i> .....	154
<i>Targeted drug delivery with nanoparticle-aptamer bioconjugates</i> .....	154
Dendrimers for anticancer drug delivery .....	155
<i>Application of dendrimers in boron neutron capture therapy</i> .....	156
<i>Application of dendrimers in photodynamic therapy</i> .....	156
<i>Dendrimer-based synthetic vector for targeted cancer gene therapy</i> .....	157
Devices for nanotechnology-based cancer therapy .....	157
<i>Convection-enhanced delivery with nanoliposomal CPT-11</i> .....	157
<i>Nanocomposite devices</i> .....	157
<i>Nanoengineered silicon for brachytherapy</i> .....	158
<i>Nanosensors for targeted drug delivery in cancer</i> .....	158
Nanoparticles combined with physical agents for tumor ablation .....	158
<i>Carbon nanotubes for laser-induced cancer destruction</i> .....	159
<i>Nanoparticles and thermal ablation</i> .....	159
<i>Nanoparticles combined with ultrasound radiation of tumors</i> .....	160
<i>Nanoparticles as adjuncts to photodynamic therapy of cancer</i> .....	160
<i>Nanoparticles for boron neutron capture therapy</i> .....	161
RNA nanotechnology for delivery of cancer therapeutics .....	161
Nanocarriers for simultaneous delivery of multiple anticancer agents.....	162
Multistage nanoparticle delivery system for penetration into tumor tissue .....	162
Combination of diagnostics and therapeutics for cancer .....	162
<i>Biomimetic nanoparticles targeted to tumors</i> .....	162
<i>Dendrimer nanoparticles for targeting and imaging tumors</i> .....	162
<i>Gold nanoparticle plus bombesin for imaging and therapy of cancer</i> .....	163
<i>Gold nanorods for diagnosis plus photothermal therapy of cancer</i> .....	163
<i>Magnetic nanoparticles for imaging as well as therapy of cancer</i> .....	164
<i>Nanobialys for combining MRI with delivery of anticancer agents</i> .....	164
<i>pHLIP nanotechnology for detection and targeted therapy of cancer</i> .....	164
<i>Radiolabeled carbon nanotubes for tumor imaging and targeting</i> .....	165
<i>Targeted therapy with magnetic nanomaterials guided by antibodies</i> .....	165
<i>Ultrasonic tumor imaging and targeted chemotherapy by nanobubbles</i> .....	165
<i>Future prospects of nanobiotechnology and targeted cancer therapy</i> .....	166
<b>Polyethylene glycol technology</b> .....	<b>166</b>
Enzon's PEG technology .....	166
Debiopharm's PEG biconjugate drug delivery platform .....	167
Nektar PEGylation .....	167
PEG Intron .....	167
<b>Single-chain antibody-binding protein technology</b> .....	<b>168</b>
<b>Vesicular systems for drug delivery in cancer</b> .....	<b>168</b>
<b>Liposomes for anticancer drug delivery</b> .....	<b>169</b>
Antibody-targeted liposomes for cancer therapy .....	169
AIZA's Stealth liposomes .....	170
Boron-containing liposomes.....	170
DepoFoam technology .....	170
Hyperthermia and liposomal drug delivery .....	171
Liposomal doxorubicin formulation with N-octanoyl-glucosylceramide .....	171
Liposome-nucleic acid complexes for anticancer drug delivery .....	171
Non-pegilated liposomal doxorubicin .....	172

Tumor-selective targeted drug delivery via folate-PEG liposomes .....	172
Ultrasound-mediated anticancer drug release from liposomes .....	172
Companies developing liposome-based anticancer drugs .....	172
<b>Pharmacosomes for controlled anticancer drug delivery .....</b>	<b>173</b>
<b>Emulsion formulations of anticancer drugs .....</b>	<b>174</b>
<b>Albumin-based drug carriers .....</b>	<b>175</b>
<b>Anticancer drugs that bind to tumors .....</b>	<b>175</b>
<b>Monoclonal antibodies .....</b>	<b>175</b>
Murine monoclonal antibodies .....	175
Humanized MABs .....	176
Actions and uses of monoclonal antibodies in cancer .....	176
Targeted antibody-based cancer therapy .....	177
<i>Antibody-cytokine fusion proteins .....</i>	<i>177</i>
<i>Antibody J591 for targeted delivery of anticancer therapy .....</i>	<i>177</i>
<i>Anti-Thomsen-Friedenreich antigen MAB .....</i>	<i>177</i>
<i>Combining MABs with anti-CD55 antibody .....</i>	<i>178</i>
<i>MABs targeted to alpha fetaprotein receptor .....</i>	<i>178</i>
<i>MABs targeted to tumor blood vessels .....</i>	<i>178</i>
<i>MABs targeted to HAAH .....</i>	<i>178</i>
<i>Velociximab .....</i>	<i>179</i>
MABs for immune activation .....	179
Delivery of cancer therapy with MABs .....	179
Antibody-directed enzyme prodrug therapy .....	180
Chemically programmed antibodies .....	181
Combining diagnostics with therapeutics based on MABs .....	181
Radiolabeled antibodies .....	182
Clinical development of MABs for treatment of cancer .....	183
Advantages and limitations of MABs for cancer therapy .....	187
Antibody drug conjugates .....	188
<b>Monoclonal T cell receptors .....</b>	<b>189</b>
<b>Radioactive materials for diagnosis and targeted therapy of cancer .....</b>	<b>189</b>
Pretargeted radioimmunotherapy of cancer .....	189
Radiolabeled somatostatin receptor antagonists .....	190
Theophylline enhances radioiodide uptake by cancer .....	190
<b>Strategies for drug delivery in cancer .....</b>	<b>190</b>
Direct introduction of anticancer drugs into the tumor .....	191
<i>Injection into the tumor .....</i>	<i>191</i>
<i>Antineoplastic drug implants into tumors .....</i>	<i>192</i>
<i>Tumor necrosis therapy .....</i>	<i>192</i>
<i>Injection into the arterial blood supply of cancer .....</i>	<i>193</i>
<i>Electrochemotherapy .....</i>	<i>194</i>
<i>Pressure-induced filtration of drugs across vessels to the tumor .....</i>	<i>195</i>
Improving drug transport to tumors .....	195
<i>Carbohydrate-enhanced chemotherapy .....</i>	<i>195</i>
<i>Dextrans as macromolecular anticancer drug carriers .....</i>	<i>196</i>
<i>In situ production of anticancer agents in tumors .....</i>	<i>196</i>
Targeted drug delivery in cancer .....	196
<i>Affibody molecules for targeted anticancer therapy .....</i>	<i>197</i>
<i>Fatty acids as targeting vectors .....</i>	<i>198</i>
<i>Genetic targeting of the kinase activity in cancer cells .....</i>	<i>198</i>
<i>Heat-activated targeted drug delivery .....</i>	<i>199</i>
<i>Novel transporters to target photosensitizers to cancer cell nuclei .....</i>	<i>199</i>
<i>Photodynamic therapy of cancer .....</i>	<i>199</i>
<i>Radionuclides delivered with receptor targeting technology .....</i>	<i>200</i>
<i>Targeting ligands specific for cancer cells .....</i>	<i>200</i>
<i>Targeting abnormal DNA in cancer cells .....</i>	<i>201</i>
<i>Targeting using a bispecific antibody .....</i>	<i>201</i>
<i>Targeted chemotherapy using transporters .....</i>	<i>201</i>
<i>Targeted generation of intracellular reactive oxygen species .....</i>	<i>202</i>
<i>Targeted delivery to receptors found in tumors .....</i>	<i>202</i>
<i>Targeted delivery by tumor-activated prodrug therapy .....</i>	<i>202</i>
<i>Targeting glutathione S-transferase .....</i>	<i>204</i>
<i>Targeting tumors by exploiting leaky blood vessels .....</i>	<i>204</i>
<i>Targeted drug delivery of anticancer agents with controlled activation .....</i>	<i>205</i>
<i>Targeted delivery of anticancer agents with ReCODE™ technology .....</i>	<i>205</i>
<i>Transmembrane Carrier Systems .....</i>	<i>206</i>
<i>Transferrin-oligomers as targeting carriers in anticancer drug delivery .....</i>	<i>206</i>
<i>Tumor targeting with peptides .....</i>	<i>206</i>
<i>Ultrasound and microbubbles for targeted anticancer drug delivery .....</i>	<i>206</i>
<i>Ultrasound for targeted delivery of chemotherapeutics .....</i>	<i>207</i>
<i>Vitamin B12 and folate for targeting cancer chemotherapy .....</i>	<i>208</i>

Cell-based drug delivery in cancer.....	209
<i>Red blood cells as vehicles for drug delivery</i> .....	210
<i>Cells as vehicles for gene delivery</i> .....	210
Drug delivery in relation to circadian rhythms.....	210
Implants for systemic delivery of anticancer drugs .....	211
<i>Drug-eluting polymer implants</i> .....	211
Angiogenesis and drug delivery to tumors .....	211
Antiangiogenesis strategies .....	212
<i>Targeting tumor endothelial cells</i> .....	212
<i>Methods for overcoming limitations of antiangiogenesis approaches</i> .....	213
Vascular targeting agents .....	213
<i>Alpha-emitting antibodies for vascular targeting</i> .....	214
<i>Angiolytic therapy</i> .....	214
<i>Anti-phosphatidylserine antibodies as VTA</i> .....	215
<i>ASA404</i> .....	215
<i>Cadherin inhibitors</i> .....	216
<i>Combretastatin A4 Prodrug</i> .....	216
<i>Drugs to induce clotting in tumor vessels</i> .....	217
<i>Selective permeation of the anticancer agent into the tumor</i> .....	217
<i>Targeted delivery of tissue factor</i> .....	218
<i>Vascular targeting agents versus antiangiogenesis agents</i> .....	218
<i>ZD6126</i> .....	219
Delivery of proteins and peptides for cancer therapy .....	219
<i>CELLECTRA™ electroporation device</i> .....	220
<i>Emisphere's eligen™ system</i> .....	220
<i>Diatos Peptide Vector intra-cellular/intra-nuclear delivery technology</i> .....	220
<i>Lytic peptides and cancer</i> .....	221
<i>Modification of proteins and peptides with polymers</i> .....	221
<i>Peptide-based targeting of cancer biomarkers for drug delivery</i> .....	222
<i>Peptide-cytokine complexes as vascular targeting agents</i> .....	222
<i>Peptide-polymer conjugates with radionuclides</i> .....	222
<i>Transduction of proteins in vivo</i> .....	223
<i>Tumor targeting by stable toxin (ST) peptides</i> .....	223
Image-guided personalized drug delivery in cancer .....	223
A computational approach to integration of drug delivery methods for cancer .....	224

#### **4. Delivery of Biological Therapies for Cancer..... 225**

<b>Introduction.....</b>	<b>225</b>
<b>Antisense therapy .....</b>	<b>225</b>
Basics of antisense approaches.....	225
Antisense cancer therapy .....	225
Mechanisms of anticancer effect of antisense oligonucleotides .....	226
Selected antisense drugs in development for cancer .....	226
<i>Antisense targeted to ribonucleotide reductase</i> .....	226
<i>Immune modulatory oligonucleotide</i> .....	227
Ribozyme therapy .....	227
Antisense drug delivery issues .....	228
Strategies to overcome delivery problems of antisense oligonucleotides.....	228
<i>Antisense delivery in microspheres</i> .....	228
<i>Delivery of antisense using nanoparticles</i> .....	229
<i>Delivery across the blood-brain barrier</i> .....	229
<i>Delivery of ribozymes</i> .....	230
<i>Iontophoretic delivery of oligonucleotides</i> .....	230
<i>Liposomes-mediated oligonucleotide delivery</i> .....	230
<i>Neugene™ antisense drugs</i> .....	230
<i>Oral delivery of oligonucleotides</i> .....	231
<i>Peptide nucleic acid delivery</i> .....	231
<i>Receptor-mediated endocytosis</i> .....	231
<i>Delivery of ribozymes</i> .....	232
Combination of antisense and electrochemotherapy .....	232
Aptamers for combined diagnosis and therapeutics of cancer.....	233
Antisense compounds in clinical trials .....	233
<b>RNA interference .....</b>	<b>234</b>
Basics of RNAi .....	234
Comparison of antisense and RNAi .....	234
RNAi applications in oncology .....	235
siRNA-based cancer immunotherapy .....	236
Delivery of siRNA in cancer .....	236
<i>Delivery of siRNA by nanoparticles</i> .....	237
<i>Delivery of siRNA by nanosize liposomes</i> .....	237
<i>Lipid nanoparticles for delivery of anticancer siRNAs</i> .....	238

<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i> .....	238
Companies developing cancer therapies based on antisense and RNAi .....	239
<b>DNA interference .....</b>	<b>240</b>
<b>Cancer gene therapy .....</b>	<b>240</b>
Basics of gene therapy .....	240
Strategies for cancer gene therapy.....	241
Gene transfer techniques as applied to cancer gene therapy.....	242
<i>Viral vectors</i> .....	242
<i>Nonviral vectors</i> .....	243
<i>A polymer approach to gene therapy for cancer</i> .....	243
Direct gene delivery to the tumor.....	244
<i>Injection into tumor</i> .....	244
<i>Reversible electroporation</i> .....	245
Hematopoietic gene transfer.....	246
<i>Genetic modification of human hematopoietic stem cells</i> .....	246
Gene-based strategies for immunotherapy of cancer (immunogene therapy).....	247
<i>Cytokine gene therapy</i> .....	247
Monoclonal antibody gene transfer .....	251
Transfer and expression of intracellular adhesion-1 molecules .....	251
Other gene-based techniques of immunotherapy of cancer.....	251
<i>Fas (Apo-1)</i> .....	251
<i>Chemokines</i> .....	251
<i>Major Histocompatibility Complex (MHC) Class I</i> .....	252
<i>IGF (Insulin-Like Growth Factor)</i> .....	252
Inhibition of immunosuppressive function .....	252
microRNA gene therapy .....	253
Delivery of toxic genes to tumor cells for eradication (molecular chemotherapy).....	253
<i>Gene-directed enzyme prodrug therapy</i> .....	253
Combination of gene therapy with radiotherapy.....	254
Multipronged therapy of cancer with microencapsulated cells.....	255
Correction of genetic defects in cancer cells (mutation compensation) .....	255
Targeted gene therapy for cancer .....	256
<i>Transcriptional targeting for cancer gene therapy</i> .....	256
<i>Targeted epidermal growth factor-mediated DNA delivery</i> .....	256
<i>Gene-based targeted drug delivery to tumors</i> .....	256
<i>Targeting gene expression to hypoxic tumor cells</i> .....	257
<i>Targeting gene expression by progression-elevated gene-3 promoter</i> .....	257
<i>Targeted delivery of retroviral particles hitchhiking on T cells</i> .....	258
<i>Targeting tumors with genetically modified T cells</i> .....	258
<i>Targeting tumors by genetically engineered stem cells</i> .....	258
<i>Tumor-targeted gene therapy by receptor-mediated endocytosis</i> .....	259
<i>Targeted site-specific delivery of anticancer genes by nanoparticles</i> .....	259
<i>Immunolipoplex for delivery of p53 gene</i> .....	259
<i>Combination of electrogene and electrochemotherapy</i> .....	260
Virus-mediated oncolysis .....	260
<i>Targeted cancer treatments based on oncolytic viruses</i> .....	260
<i>Oncolytic gene therapy</i> .....	261
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i> .....	261
<i>Facilitating oncolysis by targeting innate antiviral response by HDIs</i> .....	262
<i>Oncolytic HSV</i> .....	262
<i>Oncolytic adenoviruses</i> .....	262
<i>Oncolytic Coxsackie virus A21</i> .....	264
<i>Oncolytic vesicular stomatitis virus</i> .....	264
<i>Oncolytic measles virus</i> .....	265
<i>Oncolytic paramyxovirus</i> .....	265
<i>Oncolytic reovirus</i> .....	265
<i>Oncolytic vaccinia virus</i> .....	266
<i>Cancer terminator virus</i> .....	266
<i>Monitoring of viral-mediated oncolysis by PET</i> .....	266
<i>Companies developing oncolytic viruses</i> .....	267
Antiangiogenic therapy for cancer .....	267
Apoptotic approach to improve cancer gene therapy.....	268
Bacteria as novel anticancer gene vectors .....	269
Concluding remarks on cancer gene therapy .....	269
Cancer gene therapy companies .....	270
<b>Cell therapy for cancer.....</b>	<b>272</b>
Cellular immunotherapy for cancer .....	273
Treatments for cancer by ex vivo mobilization of immune cells .....	273
Granulocytes as anticancer agents .....	274
Neutrophil granulocytes in antibody-based immunotherapy of cancer .....	274
Use of hematopoietic stem cells for targeted cancer therapy .....	274

<b>Cancer vaccines .....</b>	<b>275</b>
Cell-based cancer vaccines.....	275
<i>Autologous tumor cell vaccines .....</i>	<i>275</i>
<i>Vaccines that simultaneously target different cancer antigens.....</i>	<i>276</i>
<i>Delivery systems for cell-based cancer vaccines.....</i>	<i>277</i>
Nucleic acid-based cancer vaccines .....	277
<i>DNA cancer vaccines .....</i>	<i>277</i>
<i>Antiangiogenic DNA cancer vaccine .....</i>	<i>278</i>
<i>Methods of delivery of DNA vaccines.....</i>	<i>278</i>
<i>RNA vaccines.....</i>	<i>279</i>
Viral vector-based cancer vaccines.....	279
Companies involved in nucleic acid-based vaccines .....	279
Genetically modified cancer cells vaccines .....	280
<i>GVAX cancer vaccines.....</i>	<i>281</i>
<i>Genetically modified dendritic cells.....</i>	<i>281</i>
Multipetide-based cancer vaccines.....	282

## **5. Delivery strategies according to cancer type and location ..... 283**

<b>Introduction.....</b>	<b>283</b>
<b>Bladder cancer .....</b>	<b>283</b>
Intravesical drug delivery.....	283
Intravesical agents combined with systemic chemotherapy .....	283
Targeted anticancer therapy for bladder cancer .....	284
Prodrug EOquin for bladder cancer .....	284
Antisense treatment of bladder cancer.....	285
Gene therapy for bladder cancer.....	285
<b>Brain tumors .....</b>	<b>286</b>
Methods for evaluation of anticancer drug penetration into brain tumor .....	286
Innovative methods of drug delivery for glioblastoma multiforme.....	286
Delivery of anticancer drugs across the blood-brain barrier .....	287
<i>Anticancer agents with increased penetration of BBB.....</i>	<i>287</i>
<i>BBB disruption.....</i>	<i>288</i>
<i>Nanoparticle-based targeted delivery of chemotherapy across the BBB.....</i>	<i>289</i>
<i>Tyrosine kinase inhibitor increases topotecan penetration into CNS .....</i>	<i>290</i>
Bypassing the BBB by alternative methods of drug delivery.....	290
<i>Intranasal perillyl alcohol .....</i>	<i>290</i>
<i>Intraarterial chemotherapy.....</i>	<i>291</i>
Enhancing tumor permeability to chemotherapy .....	291
Local delivery of chemotherapeutic agents into the tumor .....	292
<i>Carmustine biodegradable polymer implants.....</i>	<i>292</i>
<i>Fibrin glue implants containing anticancer drugs. ....</i>	<i>293</i>
<i>Biodegradable microspheres containing 5-FU.....</i>	<i>293</i>
<i>Magnetically controlled microspheres.....</i>	<i>293</i>
Convection-enhanced delivery .....	293
<i>CED for receptor-directed cytotoxin therapy .....</i>	<i>293</i>
<i>CED of topotecan .....</i>	<i>294</i>
<i>CED of a modified diphtheria toxin conjugated to transferrin .....</i>	<i>294</i>
<i>CED of nanoliposomal CPT-11.....</i>	<i>295</i>
<i>CED for delivery <sup>131</sup>I-chTNT-1/B MAb .....</i>	<i>295</i>
Anticancer drug formulations for targeted delivery to brain tumors .....	295
<i>Lipid-coated microbubbles as a delivery vehicle for taxol.....</i>	<i>295</i>
<i>Liposomes for drug delivery to brain tumors.....</i>	<i>295</i>
<i>MAbs targeted to brain tumors .....</i>	<i>296</i>
<i>Multiple targeted drugs for brain tumors .....</i>	<i>296</i>
<i>Nanoparticles for targeted drug delivery in glioblastoma multiforme.....</i>	<i>297</i>
<i>Targeted antiangiogenic/apoptotic/cytotoxic therapies .....</i>	<i>298</i>
Introduction of the chemotherapeutic agent into the CSF pathways.....	299
<i>Intraventricular chemotherapy for meningeal cancer .....</i>	<i>299</i>
<i>Intrathecal chemotherapy .....</i>	<i>299</i>
Interstitial delivery of dexamethasone for reduction of peritumor edema.....	300
Combination of chemotherapy with radiotherapy.....	300
Photodynamic therapy for chemosensitization of brain tumors .....	300
<i>Nanoparticles for photodynamic therapy of brain tumors.....</i>	<i>301</i>
Innovative delivery of radiotherapy to brain tumors .....	301
<i>GliaSite Radiation Therapy System.....</i>	<i>301</i>
<i>Boron neutron capture therapy for brain tumors .....</i>	<i>301</i>
Cell therapy for glioblastoma multiforme .....	302
<i>Mesenchymal stem cells to deliver treatment for gliomas .....</i>	<i>302</i>
Gene therapy for glioblastoma multiforme.....	302
<i>Antiangiogenic gene therapy .....</i>	<i>303</i>
<i>Anticancer drug delivery by genetically engineered MSCs .....</i>	<i>304</i>

<i>Intravenous gene delivery with nanoparticles into brain tumors</i> .....	304
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i> .....	304
<i>Neural stem cells for drug/gene delivery to brain tumors</i> .....	305
<i>Peptides targeted to glial tumor cells</i> .....	306
<i>RNAi gene therapy of brain cancer</i> .....	306
<i>Single-chain antibody-targeted adenoviral vectors</i> .....	306
<i>Targeting normal brain cells with an AAV vector encoding interferon-<math>\beta</math></i> .....	307
<i>Treatment of medulloblastoma by suppressing genes in Shh pathway</i> .....	307
<i>Virus-mediated oncolytic therapy of brain cancer</i> .....	307
Vaccination for glioblastoma multiforme.....	310
<b>Breast Cancer</b> .....	<b>310</b>
Therapies for breast cancer involving innovative methods of drug delivery .....	310
Injectable biodegradable polymer delivery system for local chemotherapy .....	311
MammoSite brachytherapy.....	311
Monoclonal antibodies targeted to HER2 receptor.....	311
Breast cancer vaccines .....	312
<i>HER-2 DNA AutoVac™ vaccine</i> .....	312
<i>Recombinant adenoviral ErbB-2/neu vaccine</i> .....	313
<i>Gene vaccine for breast cancer</i> .....	313
<i>NeuVax</i> .....	314
Gene therapy for breast cancer.....	315
Antisense therapy for breast cancer .....	315
Inhibitors of growth factors FGF2 and VEGF for breast cancer .....	316
Targeted multi-drug delivery approach to breast cancer.....	316
<b>Cancer of the cervix and the uterus</b> .....	<b>316</b>
Gene therapy for cervical cancer.....	316
Delivery of chemoradiation therapy .....	316
Cervical cancer vaccines .....	317
<b>Colorectal cancer</b> .....	<b>317</b>
Perifosine.....	317
Oxaliplatin long-circulating liposomes.....	318
<b>Cancer of the liver</b> .....	<b>318</b>
Hepatocellular carcinoma .....	318
Treatment of liver metastases .....	319
<b>Leukemia</b> .....	<b>319</b>
<i>Clofarabine</i> .....	320
<b>Malignant melanoma</b> .....	<b>320</b>
Targeted therapies for melanoma.....	321
Immunotherapy for malignant melanoma.....	321
Gene therapy for malignant melanoma .....	322
<b>Neuroblastoma</b> .....	<b>324</b>
Genetically modified NSCs for treatment of neuroblastoma .....	324
<b>Non-Hodgkin's lymphoma</b> .....	<b>324</b>
Pixastrone .....	324
<b>Non-small cell lung cancer</b> .....	<b>325</b>
Aerosol delivery of anticancer agents for lung cancer.....	326
Aerosol gene delivery for lung cancer .....	326
Complex nanoscale pulmonary delivery of drugs for resistant lung cancer .....	327
Intratumoral administration of anticancer drugs through a bronchoscope .....	327
<b>Ovarian cancer</b> .....	<b>327</b>
Innovative drug delivery for ovarian cancer .....	327
Intraperitoneal delivery .....	328
Dendritic cell vaccination for ovarian cancer .....	329
Gene Therapy for ovarian cancer .....	329
<b>Pancreatic cancer</b> .....	<b>330</b>
Targeted chemotherapy for pancreatic cancer.....	330
Local anticancer drug delivery for pancreatic cancer .....	330
Vaccine for pancreatic cancer .....	331
Gene therapy for pancreatic cancer .....	331
<i>Adenovirus-mediated transfer of vasostatin gene</i> .....	331
<i>Rexin-G™ for targeted gene delivery in pancreatic cancer</i> .....	331
<i>Targeted Expression of BikDD gene</i> .....	332
<b>Prostate cancer</b> .....	<b>332</b>
PACLIMER Microspheres .....	333
PRX302 .....	333
Brachytherapy for cancer of prostate .....	333
Capridine-beta.....	334
LHRH for prostate cancer .....	334
<i>LHRH analogs</i> .....	334
<i>Histrelin implant</i> .....	335
Immunomodulatory drugs.....	335

MABs for prostate cancer .....	335
Targeted therapies for prostate cancer .....	336
<i>Delivery of cisplatin to prostate cancer by nanoparticles</i> .....	336
<i>Delivery of siRNAs to prostate cancer with aptamer-siRNA chimeras</i> .....	336
<i>Delivery of siRNA for prostate cancer with metastases</i> .....	336
<i>PSA-activated protoxin that kills prostate cancer</i> .....	336
<i>Targeted drug delivery with nanoparticle-aptamer bioconjugates</i> .....	337
<i>Targeted delivery of a nanoparticulate platinum prodrug</i> .....	337
<i>Targeting oncogene MDM2 in prostate cancer</i> .....	338
<i>Vascular targeting of prostate cancer</i> .....	338
Gene therapy for cancer of prostate .....	338
<i>Experimental studies</i> .....	338
<i>Nanoparticle-based gene therapy for prostate cancer</i> .....	339
<i>Tumor suppressor gene therapy in prostate cancer</i> .....	339
<i>Vaccines for prostate cancer</i> .....	339
<i>Clinical trials of gene therapy for prostate cancer</i> .....	340
<i>Combined approaches</i> .....	341
<i>Combined autovaccination and hyperthermia</i> .....	341
<b>6. Cancer drug delivery markets .....</b>	<b>343</b>
<b>Introduction.....</b>	<b>343</b>
Global markets for drug delivery .....	343
Estimation of cancer drug delivery markets .....	343
<i>Methods used for market estimation</i> .....	343
<i>Cancer epidemiology</i> .....	344
<i>Cost of patient care in cancer</i> .....	345
<b>Market forecasts 2011-2021 .....</b>	<b>346</b>
Cancer drug market .....	346
<i>Markets for leukemia</i> .....	347
<i>Markets for brain tumors</i> .....	347
<i>Geographical distribution of cancer markets</i> .....	347
Factors affecting future cancer markets .....	348
<b>Market share according to cancer drug delivery technologies .....</b>	<b>348</b>
Antiangiogenesis therapies .....	349
Antineoplastic drug implants for systemic administration .....	349
Antisense therapy and RNAi .....	349
Cancer vaccines .....	350
Gene therapy .....	350
Liposomes for anticancer drugs.....	350
Monoclonal antibodies .....	351
<b>Strategic aspects of cancer drug delivery .....</b>	<b>351</b>
<b>Unmet needs in cancer drug delivery .....</b>	<b>351</b>
<b>Future prospects of cancer drug delivery .....</b>	<b>352</b>
Cancer drug delivery and pharmacogenomics .....	352
Drug delivery for cancer in the postgenomic era .....	353
Role of nanobiotechnology in development of cancer drug delivery markets .....	353
Expansion of cancer drug delivery markets in developing countries .....	353
Drivers for the development of drug delivery technologies in cancer .....	353
<b>7. References.....</b>	<b>355</b>

## Tables

Table 1-1: Estimated new cases of cancer in the US at most involved organs – 2008 .....	35
Table 1-2: Historical landmarks in drug delivery for cancer .....	38
Table 2-1: Innovative strategies against cancer .....	39
Table 2-2: A classification of antiangiogenic therapies .....	42
Table 2-3: Antiangiogenic agents in clinical trials .....	48
Table 2-4: Approaches to cancer therapy based on bacteria .....	49
Table 2-5: Cell therapy technologies used for cancer .....	55
Table 2-6: Non-nucleic acid cancer vaccines without genetic modification .....	57
Table 2-7: Cellular pathways as targets for anticancer therapies.....	75
Table 2-8: Examples of anticancer agents that target mitochondrial membranes .....	77
Table 2-9: Drugs targeting oncogenes.....	81
Table 2-10: Cancer therapies based on the P53 .....	104
Table 2-11: Promise of personalized therapy in cancer .....	108
Table 2-12: Companies developing personalized therapy for cancer .....	108
Table 3-1: Routes of drug delivery in cancer .....	116
Table 3-2: Systemic intravenous drug delivery systems for chemotherapy of cancer .....	116

Table 3-3: Microparticles as therapeutic delivery systems in cancer .....	130
Table 3-4: Classification of nanobiotechnology approaches to drug delivery in cancer .....	135
Table 3-5: Approved anticancer drugs using nanocarriers .....	136
Table 3-6: Clinical trials of anticancer drugs using nanocarriers .....	136
Table 3-7: Liposome-based anticancer drug delivery .....	173
Table 3-8: Approved monoclonal antibodies for cancer .....	176
Table 3-9: Anticancer agents linked to monoclonal antibodies .....	179
Table 3-10: Monoclonal antibodies in clinical trials for cancer .....	183
Table 3-11: Antibody drug conjugates in clinical trials for cancer .....	188
Table 3-12: Strategies for drug delivery in cancer .....	190
Table 3-13: Implant systems for delivery of anticancer drugs into tumors .....	192
Table 3-14: Systemic delivery of drugs targeted to the tumor .....	197
Table 3-15: Methods of delivery of antiangiogenesis therapies .....	212
Table 3-16: Companies developing vascular targeting agents .....	214
Table 4-1: Mechanisms of anticancer effect of antisense oligonucleotides .....	226
Table 4-2: Methods of delivery of oligonucleotides for cancer therapy .....	228
Table 4-3: Antisense oligonucleotides in clinical trials for cancer .....	233
Table 4-4: Companies developing antisense and RNAi therapies for cancer .....	239
Table 4-5: Strategies for cancer gene therapy .....	241
Table 4-6: Enzyme/prodrug combinations employed in suicide gene therapy .....	253
Table 4-7: Mutation compensation strategies used clinically .....	255
Table 4-8: Companies developing oncolytic viruses .....	267
Table 4-9: Companies involved in cancer gene therapy .....	270
Table 4-10: Cell therapy technologies used for cancer .....	272
Table 4-11: Companies developing nucleic acids/genetically modified cells-based cancer vaccines .....	280
Table 5-1: Innovative methods of drug delivery for glioblastoma multiforme .....	286
Table 5-2: Strategies for gene therapy of malignant brain tumors .....	302
Table 5-3: Therapies for breast cancer involving innovative methods of drug delivery .....	310
Table 5-4: Drug delivery for hepatocellular carcinoma .....	318
Table 5-5: Gene therapy for malignant melanoma .....	322
Table 5-6: Targeted treatment of non-small cell lung cancer .....	325
Table 5-7: Clinical trials of gene therapy in ovarian cancer .....	329
Table 5-8: Methods of drug delivery in pancreatic cancer .....	330
Table 5-9: Pharmacological strategies under investigation for cancer of the prostate .....	332
Table 5-10: Clinical trials of gene therapy for prostate cancer .....	340
Table 6-1: Worldwide drug delivery market growth 2011 to 2021 .....	343
Table 6-2: Estimated worldwide prevalence of cancer according to type of cancer .....	344
Table 6-3: Estimated number of cancer patients in major markets 2011-2021 .....	345
Table 6-4: Worldwide anticancer drug sales for selected cancers from 2011 to 2021 .....	347
Table 6-5: Geographical distribution of cancer markets 2011-2021 .....	348
Table 6-6: Market values of cancer drug delivery technologies from 2011-2021 .....	348

## Figures

Figure 1-1: An overview of some key steps in tumor angiogenesis .....	30
Figure 2-1: Schematic role of T-helper cells in immune response to cancer .....	59
Figure 3-1: Cyclacel's Penetratin Transport System for delivery of drugs to targets .....	127
Figure 3-2: Micelle for drug delivery in cancer .....	140
Figure 3-3: Mechanism of action of Targaceutical drugs .....	198
Figure 3-4: ALZA's DUROS implant .....	211
Figure 5-1: A concept of targeted drug delivery to GBM across the BBB .....	289
Figure 6-1: Unmet needs in cancer drug delivery .....	352